Tag: Usp 797

According to the FDA, poor compounding practices can result in contaminated drugs, leading to serious injury or death. A key **example of a high risk compounding** is the preparation of sterile injectables from non-sterile raw drug powders, a process that requires meticulous controls and terminal sterilization.

Over 90% of all ophthalmic medications are delivered topically, making the proper compounding of eye preparations critical for patient safety and efficacy. To ensure safety, a pharmacist must carefully evaluate which of the following are considerations when compounding an ophthalmic preparation, including sterility, tonicity, and pH.

In a study assessing compounding practices, over one-third of IV preparations were found to exceed the >10% additive volume guideline, highlighting a common source of medication errors. This critical finding underscores the importance of understanding and implementing **what is the 10 rule for IV compounding** to ensure accurate drug concentrations and mitigate patient risk.